Allelic loss of chromosome 1p36 in neuroblastoma is of preferential maternal origin and correlates with N–myc amplification

Caron, Huib N.; Sluis, Peter van; Hoeve, Melanie van; Kraker, Jan de; Bras, Johannes; Slater, Rosalyn; Mannens, Marcel; Voûte, P. A.; Westerveld, A.; Versteeg, Rogier

doi:10.1038/ng0693-187

Cited by 126 publications

(85 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Examples include rhabdomyosarcoma (maternal chromosome 11p15.5) (Scrable et al, 1989), neuroblastoma (maternal chromosome 1p36 or paternal chromosome 2) (Caron et al, 1993), and acute myeloblastic leukemia (paternal chromosome 7) (Katz et al, 1992). These observations suggest an involvement of imprinted genes in tumor-initiation or progression processes.…”

Section: Discussionmentioning

confidence: 94%

Two paternal genomes are compatible with dopaminergic in vitro and in vivo differentiation

Choi¹,

Eckardt²,

Ahmad³

et al. 2010

Int. J. Dev. Biol.

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 94%

Two paternal genomes are compatible with dopaminergic in vitro and in vivo differentiation

Choi¹,

Eckardt²,

Ahmad³

et al. 2010

Int. J. Dev. Biol.

View full text Add to dashboard Cite

“…To sustain growth of the most aggressive form of neuroblastoma, these MYCN-amplified neuroblastoma cells may acquire mechanisms that suppresses MIZ-1 expression. Because MIZ-1 resides in 1p36 and the deletion of this chromosomal region is associated with MYCN amplification (31,32), a copy of MIZ-1 is likely to be deleted in MYCNamplified neuroblastoma, resulting in low MIZ-1 expression in these tumors. It was therefore not surprising that MIZ-1 expression lost its prognostic significance in a two-variable Cox regression analysis against MYCN amplification (Table 1).…”

Section: Discussionmentioning

confidence: 99%

De novo Identification of MIZ-1 (ZBTB17) Encoding a MYC-Interacting Zinc-Finger Protein as a New Favorable Neuroblastoma Gene

Ikegaki¹,

Gotoh²,

Kung³

et al. 2007

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: Neuroblastoma is a childhood cancer that exhibits either a favorable or an unfavorable phenotype. Favorable neuroblastoma genes (EPHB6, EFNB2, EFNB3, NTRK1, and CD44) are genes whose high-level expression predicts favorable neuroblastoma disease outcome. Accordingly, the forced expression of these genes or their reactivation by gene silencing inhibitors in unfavorable neuroblastoma cells results in suppression of tumor growth and metastases. This study was undertaken to design an experimental strategy to identify additional favorable neuroblastoma genes. Experimental Design: Favorable neuroblastoma gene candidates were first identified by gene expression profiling analysis on IMR5 neuroblastoma cells treated with inhibitors of DNA methylation and histone deacetylase against the untreated control cells. Among the candidates, we focused on MIZ-1, which encodes a MYC-interacting zinc-finger protein, because it is known to enhance the expression of growth suppressive genes, such as CDKN1A. Results: High-level MIZ-1 expression was associated with favorable disease outcome of neuroblastoma (P = 0.0048). Forced MIZ-1expression suppressed in vitro growth of neuroblastoma cell lines. High MIZ-1 expression was correlated with the small-size neuroblastoma xenografts treated with gene silencing inhibitors or a glucocorticoid. In addition, forced MIZ-1 expression enhanced the expression of CD44 and EFNB2 inneuroblastoma celllines in vitro. Furthermore, MIZ-1 expression was positively correlated with the expression of favorable neuroblastoma genes (EFNB2, EFNB3, EPHB6, and NTRK1) in the human neuroblastoma xenograft therapeutic models. Conclusion: MIZ-1 is a new favorable neuroblastoma gene, which may directly or indirectly regulate the expression of other favorable neuroblastoma genes.

show abstract

“…The most frequent genetic abnormality reported to date is the deletion of the short arm of chromosome 1 (Brodeur et al, 1981;Gilbert et al, 1984). Recent investigations have reported that the frequency of loss of heterozygosity (LOH) in 1p ranged from 20 to 89% (Fong et al, 1989(Fong et al, , 1992Suzuki et al, 1989;Weith et al, 1989;Takayama et al, 1992;Caron et al, 1993Caron et al, , 1996Schleiermacher et al, 1994;Takeda et al, 1994;Martinsson et al, 1995), and two or more tumour suppressor genes have been thought to be located in chromosome 1p (Schleiermacher et al, 1994;Takeda et al, 1994;Caron et al, 1995;Cheng et al, 1995). However, the genes on chromosome 1 responsible for NB have not yet been reported.…”

mentioning

confidence: 99%

Detailed deletion mapping of chromosome band 14q32 in human neuroblastoma defines a 1.1-Mb region of common allelic loss

et al. 2000

View full text Add to dashboard Cite

Neuroblastoma (NB) is a well-known malignant disease in infants, but its molecular mechanisms have not yet been fully elucidated. To investigate the genetic contribution of abnormalities on the long arm of chromosome 14 (14q) in NB, we analysed loss of heterozygosity (LOH) in 54 primary NB samples using 12 microsatellite markers on 14q32. Seventeen (31%) of 54 tumours showed LOH at one or more of the markers analysed, and the smallest common region of allelic loss was identified between D14S62 and D14S987. This region was estimated to be 1-cM long from the linkage map. Fluorescence in situ hybridization also confirmed the loss. There was no statistical correlation between LOH and any clinicopathologic features, including age, stage, amplification of MYCN and ploidy. We further constructed a contig spanning the lost region using bacterial artificial chromosome and estimated this region to be approximately 1.1-Mb by pulsed-field gel electrophoresis. Our results will contribute to cloning and characterizing the putative tumour-associated gene(s) in 14q32 in NB. © 2000 Cancer Research Campaign

show abstract

Allelic loss of chromosome 1p36 in neuroblastoma is of preferential maternal origin and correlates with N–myc amplification

Cited by 126 publications

References 21 publications

Two paternal genomes are compatible with dopaminergic in vitro and in vivo differentiation

Two paternal genomes are compatible with dopaminergic in vitro and in vivo differentiation

De novo Identification of MIZ-1 (ZBTB17) Encoding a MYC-Interacting Zinc-Finger Protein as a New Favorable Neuroblastoma Gene

Detailed deletion mapping of chromosome band 14q32 in human neuroblastoma defines a 1.1-Mb region of common allelic loss

Contact Info

Product

Resources

About